CD3
Showing 1 - 25 of >10,000
![](/image/sponsor/kazakhstan's_medical_university_"ksph")
Health Status of Children Born After Assisted Reproductive
Recruiting
- Children Born After Assisted Reproductive Technologies
- +2 more
- hemogram examination
-
Almaty, KazakhstanSevara ilmuratova
Oct 17, 2023
Solid Tumor Trial (BS006 Injection)
Not yet recruiting
- Solid Tumor
- BS006 Injection
- (no location specified)
Jul 3, 2023
Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)
Not yet recruiting
- Advanced Prostate Cancer
-
Lyon, France
- +2 more
Oct 18, 2023
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
Immune Markers in Pediatric ITP
Not yet recruiting
- ITP - Immune Thrombocytopenia
- complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
- (no location specified)
Oct 17, 2023
Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)
Not yet recruiting
- Glioblastoma Multiforme of Brain
- CHM-1101 CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 19, 2022
Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)
Not yet recruiting
- Malignant Glioma
- Glioblastoma
- hEGFRvIII-CD3 (BRiTE)
- Activated Cell Therapy
-
Durham, North CarolinaDuke University Medical Center
Jun 24, 2022
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)
Not yet recruiting
- Classical Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- GEN3017
- (no location specified)
Aug 25, 2023
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
AML, Childhood Trial in United States (CD33*CD3 BsAb)
Active, not recruiting
- AML, Childhood
- CD33*CD3 BsAb
-
Birmingham, Alabama
- +12 more
Jan 12, 2023
Recurrent or Metastatic Solid Tumors Trial (Recombinant Anti-EpCAM-CD3 Antibody Injection)
Not yet recruiting
- Recurrent or Metastatic Solid Tumors
- Recombinant Anti-EpCAM-CD3 Antibody Injection
- (no location specified)
Oct 17, 2023
Systemic Lupus Erythematosus, Systemic Sclerosis Trial in Philadelphia (Depletion of CD3/CD19 in an autologous stem cell
Recruiting
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Depletion of CD3/CD19 in an autologous stem cell transplant
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
May 23, 2022
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma Trial in Duarte (Chlorotoxin
Recruiting
- Recurrent Glioblastoma
- +3 more
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 25, 2022
Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes Trial in Philadelphia (Transplant of stem cells with
Recruiting
- Leukemia
- +4 more
- Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Nov 2, 2021
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)
Withdrawn
- Leukemia
- Stem Cell Transplantation
-
Munich, Bavaria, Germany3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Acalabrutinib
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jun 16, 2022
Primary Immunodeficiency, PID Trial in Pittsburgh (CD3/CD19 neg allogeneic BMT)
Active, not recruiting
- Primary Immunodeficiency
- PID
- CD3/CD19 neg allogeneic BMT
-
Pittsburgh, PennsylvaniaChildren's Hospital of Pittsburgh of University of Pittsburgh Me
Oct 6, 2021
Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma Trial in Milwaukee (XmAb18968 - Dose
Recruiting
- Acute Myeloid Leukemia
- +2 more
- XmAb18968 - Dose level -1
- +4 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Feb 15, 2022
Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +5 more
-
Noblesville, IndianaInvestigative Clinical Research of Indiana
Oct 18, 2023
Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +6 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection Trial in Los Angeles (Donor CD34+,
Not yet recruiting
- End Stage Kidney Disease
- +3 more
- Donor CD34+, CD3+. and belumosudil
-
Los Angeles, CaliforniaUniversity of California, Los Angeles
Apr 6, 2023
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
- Odronextamab
- +5 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
